Candriam SCA’s Tenax Therapeutics TENX Stock Holding History

Candriam SCA’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.9M	Buy	+749,588	New	+$9.58M	0.05%	279

Other funds holding TENX

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Candriam SCA's TENX Position: Q2 2026 in Review

Candriam SCA opened a new position in Tenax Therapeutics (TENX) in Q2 2026: 749,588 shares worth $10.9M. The stake represents 0.05% of the portfolio and ranks #279 among its holdings.

99 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

Candriam SCA held 749,588 shares of Tenax Therapeutics worth $10.9M as of Q2 2026.
Tenax Therapeutics was a new Candriam SCA position in Q2 2026.
Tenax Therapeutics made up 0.05% of Candriam SCA's portfolio in Q2 2026, its #279 holding.
99 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.